Journal: Frontiers in Pharmacology

Article Title: Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

doi: 10.3389/fphar.2023.1285374

Figure Lengend Snippet: A list of selected phase 3 clinical trials evaluating the efficacy of ALK inhibitors in non-small cell lung cancer.

Article Snippet: It is a multitarget TKI, which inhibits ALK, mesenchymal epithelial transition growth factor (c‐MET) and ROS proto-oncogene 1 receptor kinase (ROS1) ( ).

Techniques: Clinical Proteomics

Journal: Expert opinion on drug discovery

Article Title: Novel approaches and current challenges with targeting the endocannabinoid system

doi: 10.1080/17460441.2020.1752178

Figure Lengend Snippet: Structure of allosteric cannabinoids: ORG27759, ORG29647, GAT211, ZCZ011, PSNCBAM-1, lipoxin A4, pregnenolone, RTI-371, DHGA, trans-β-caryophyllene and structure of the agonist CB1/CB2 CP55,940.

Article Snippet: The neuroprotective effects of this molecule were proved to be mediated by activation of PPAR-γ. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 4. caption a7 Structure of multitarget cannabinoids: CB-quinones HU-311 [ 71 ], VCE-004.8 and VCE-003.2 [ 67 , 68 ] and chromenopyrazolediones 4 and 10 [ 69 , 70 ]; indazolylketones 5 and 6 [ 75 ]; diarylpyrazole derivative 4 [ 76 ]; 1,2-dihydro-2-oxo-pyridine-3-carboxamide B1 [ 77 ] and CB-opioid bivalent ligands 11 and 19 [ 86 ].

Techniques:

Journal: Expert opinion on drug discovery

Article Title: Novel approaches and current challenges with targeting the endocannabinoid system

doi: 10.1080/17460441.2020.1752178

Figure Lengend Snippet: Structure of pheripheral cannabinoids: AM6545, TM38837, PrNMI, TXX522, LEI-101, DBPR211.

Article Snippet: The neuroprotective effects of this molecule were proved to be mediated by activation of PPAR-γ. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 4. caption a7 Structure of multitarget cannabinoids: CB-quinones HU-311 [ 71 ], VCE-004.8 and VCE-003.2 [ 67 , 68 ] and chromenopyrazolediones 4 and 10 [ 69 , 70 ]; indazolylketones 5 and 6 [ 75 ]; diarylpyrazole derivative 4 [ 76 ]; 1,2-dihydro-2-oxo-pyridine-3-carboxamide B1 [ 77 ] and CB-opioid bivalent ligands 11 and 19 [ 86 ].

Techniques:

Journal: Expert opinion on drug discovery

Article Title: Novel approaches and current challenges with targeting the endocannabinoid system

doi: 10.1080/17460441.2020.1752178

Figure Lengend Snippet: Structure of multitarget cannabinoids: CB-quinones HU-311 [71], VCE-004.8 and VCE-003.2 [67,68] and chromenopyrazolediones 4 and 10 [69,70]; indazolylketones 5 and 6 [75]; diarylpyrazole derivative 4 [76]; 1,2-dihydro-2-oxo-pyridine-3-carboxamide B1 [77] and CB-opioid bivalent ligands 11 and 19 [86]. Numbers that have been attributed to the structures refer to the corresponding number in original articles.

Article Snippet: The neuroprotective effects of this molecule were proved to be mediated by activation of PPAR-γ. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 4. caption a7 Structure of multitarget cannabinoids: CB-quinones HU-311 [ 71 ], VCE-004.8 and VCE-003.2 [ 67 , 68 ] and chromenopyrazolediones 4 and 10 [ 69 , 70 ]; indazolylketones 5 and 6 [ 75 ]; diarylpyrazole derivative 4 [ 76 ]; 1,2-dihydro-2-oxo-pyridine-3-carboxamide B1 [ 77 ] and CB-opioid bivalent ligands 11 and 19 [ 86 ].

Techniques:

Journal: Expert opinion on drug discovery

Article Title: Novel approaches and current challenges with targeting the endocannabinoid system

doi: 10.1080/17460441.2020.1752178

Figure Lengend Snippet: Structure of endocannabinoids virodhamine, noladin ether, oleylethanolamide and palmitoylethanolamide; putativee endogenous ligands for GPR55 and GPR18 LPI and NAGly; and synthetic cannabinoids HU210, JWH133, O-1602, Abn-CBD, SR141716A and SR144528.

Article Snippet: The neuroprotective effects of this molecule were proved to be mediated by activation of PPAR-γ. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 4. caption a7 Structure of multitarget cannabinoids: CB-quinones HU-311 [ 71 ], VCE-004.8 and VCE-003.2 [ 67 , 68 ] and chromenopyrazolediones 4 and 10 [ 69 , 70 ]; indazolylketones 5 and 6 [ 75 ]; diarylpyrazole derivative 4 [ 76 ]; 1,2-dihydro-2-oxo-pyridine-3-carboxamide B1 [ 77 ] and CB-opioid bivalent ligands 11 and 19 [ 86 ].

Techniques:

Journal: Expert opinion on drug discovery

Article Title: Novel approaches and current challenges with targeting the endocannabinoid system

doi: 10.1080/17460441.2020.1752178

Figure Lengend Snippet: Summary of potential approaches to target the ECS. A) Modulation at CB1 and CB2 receptors (G-prot refers to G protein signaling and β-arr to β-arrestin1 or 2 pathways). B) Other targets of cannabinoids.

Article Snippet: The neuroprotective effects of this molecule were proved to be mediated by activation of PPAR-γ. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 4. caption a7 Structure of multitarget cannabinoids: CB-quinones HU-311 [ 71 ], VCE-004.8 and VCE-003.2 [ 67 , 68 ] and chromenopyrazolediones 4 and 10 [ 69 , 70 ]; indazolylketones 5 and 6 [ 75 ]; diarylpyrazole derivative 4 [ 76 ]; 1,2-dihydro-2-oxo-pyridine-3-carboxamide B1 [ 77 ] and CB-opioid bivalent ligands 11 and 19 [ 86 ].

Techniques: